Advanced search
Publication Cover
Therapeutic Delivery Volume 2, 2011 - Issue 3
Submit an article Journal homepage
124
Views
1
CrossRef citations to date
0
Altmetric
Review

Quantitative and Specific Molecular Imaging of Cancer With Labeled Engineered Monoclonal Antibody Fragments

Lauren T Rosenblum1 Molecular Imaging Program Center for Cancer Research National Cancer Institute NIHBuilding 10Room B3B69 10 Center Dr. BethesdaMD20892-1088USA
,
Peter L Choyke1 Molecular Imaging Program Center for Cancer Research National Cancer Institute NIHBuilding 10Room B3B69 10 Center Dr. BethesdaMD20892-1088USA
&
Hisataka Kobayashi1 Molecular Imaging Program Center for Cancer Research National Cancer Institute NIHBuilding 10Room B3B69 10 Center Dr. BethesdaMD20892-1088USA;2 [email protected]
Pages 345-358 | Published online: 09 Mar 2011

Bibliography

  • Holliger P , HudsonPJ. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol.23(9), 1126–1136 (2005).
  • Carter P , MerchantAM. Engineering antibodies for imaging and therapy. Curr. Opin. Biotechnol.8(4), 449–454 (1997).
  • Wu AM , OlafsenT. Antibodies for molecular imaging of cancer. Cancer J.14(3), 191–197 (2008).
  • Paul WE . Fundamental Immunology (6th Edition). Lippincott Williams & Wilkins, PA, USA 126–129 (2008).
  • Sompayrac L . B Cells and Antibodies. In: How the Immune System Works (2nd Edition). Blackwell Science, Oxford, UK (2003).
  • Jain M , KamalN, BatraSK. Engineering antibodies for clinical applications. Trends Biotechnol.25(7), 307–316 (2007).
  • Batra SK , JainM, WittelUA, ChauhanSC, ColcherD. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol.13(6), 603–608 (2002).
  • van Dongen G , VisserGWM, HoogeM, De Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist12(12), 1379–1389 (2007).
  • Weiner LM , SuranaR, WangSZ. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol.10(5), 317–327 (2010).
  • Ludwig JA , WeinsteinJN. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer5(11), 845–856 (2005).
  • Porter RR . Hydrolysis of rabbit γ-globulin and antibodies with crystalline papain. Biochem. J.73, 119–126 (1959).
  • Nisonoff A , WisslerFC, LipmanLN, WoernleyDL. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch. Biochem. Biophys.89(2), 230–244 (1960).
  • Kenanova V , WuAM. Tailoring antibodies for radionuclide delivery. Expert Opin. Drug Deliv.3(1), 53–70 (2006).
  • Huston JS , McCartneyJ, TaiMSet al. Medical applications of single-chain antibodies. Int. Rev. Immunol 10(2–3), 195–217 (1993).
  • Begent RHJ , VerhaarMJ, ChesterKAet al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library. Nat. Med. 2(9), 979–984 (1996).
  • Reiter Y , BrinkmannU, LeeBK, PastanI. Engineering antibody Fv fragments for cancer detection and therapy: disulfide-stabilized Fv fragments. Nat. Biotechnol.14(10), 1239–1245 (1996).
  • Nilsson FY , TolmachevV. Affibody® molecules: new protein domains for molecular imaging and targeted tumor therapy. Curr. Opin. Drug Discov. Dev.10(2), 167–175 (2007).
  • Tolmachev V , OrlovaA, NilssonFY, FeldwischJ, WennborgA, AbrahmsenL. Affibody molecules: potential for in vivo imaging of molecular targets for cancer therapy. Expert Opin. Biol. Ther.7(4), 555–568 (2007).
  • Todorovska A , RooversRC, DolezalO, KorttAA, HoogenboomHR, HudsonPJ. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods248(1–2), 47–66 (2001).
  • Cuesta AM , Sainz-PastorN, BonetJ, Baldomero Oliva B, A‘lvarez-Vallina L. Multivalent antibodies: when design surpasses evolution. Trends Biotechnol.28(7), 355–62 (2010)
  • Kortt AA , DolezalO, PowerBE, HudsonPJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol. Eng.18(3), 95–108 (2001).
  • Sheikholvaezin A , ErikssonD, AhlstromKR, JohanssonL, StigbrandT. Tumor radioimmunolocalization in nude mice by mono- and divalent-single-chain Fv antiplacental alkaline phosphatase antibodies. Cancer Biother. Radiopharm.22(1), 64–72 (2007).
  • Xiong CY , NatarajanA, ShiXB, DenardoGL, DenardoSJ. Development of tumor targeting anti-MUC-1 multimer: effects of di-scFv unpaired cysteine location on PEGylation and tumor binding. Protein Eng. Des. Sel.19(8), 359–367 (2006).
  • Berndorff D , BorkowskiS, MoosmayerDet al. Imaging of tumor angiogenesis using Tc-99m-labeled human recombinant anti-ED-B fibronectin antibody fragments. J. Nucl. Med. 47(10), 1707–1716 (2006).
  • Hu SZ , ShiveryL, RaubitschekAet al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-C(h)3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. 56(13), 3055–3061 (1996).
  • Cuesta AM , Sanchez-MartinD, SanzLet al. In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences. PLoS One4(4), 9 (2009).
  • Ferl GZ , KenanovaV, WuAM, DiStefanoJJ. A two-tiered physiologically based model for dually labeled single-chain Fv–Fc antibody fragments. Mol. Cancer Ther.5(6), 1550–1558 (2006).
  • Adams GP , SchierR, MarshallKet al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. Cancer Res. 58(3), 485–490 (1998).
  • Sundaresan G , YazakiPJ, ShivelyJEet al. I-124-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. J. Nucl. Med. 44(12), 1962–1969 (2003).
  • Silacci M , BrackSS, SpathNet al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. Protein Eng. Des. Sel. 19(10), 471–478 (2006).
  • Kelly MP , LeeFT, TahtisKet al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. Cancer Biother. Radiopharm. 23(4), 411–423 (2008).
  • Heo MA , KimSH, KimSYet al. Functional expression of single-chain variable fragment antibody against c-MET in the cytoplasm of Escherichia coli. Protein Expr. Purif. 47(1), 203–209 (2006).
  • Schneider DW , HeitnerT, AlickeBet al. In vivo biodistribution, PET imaging, and tumor accumulation of Y-86- and In-111-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. J. Nucl. Med.50(3), 435–443 (2009).
  • Leyton JV , OlafsenT, ShermanMAet al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. Protein Eng. Des. Sel. 22(3), 209–216 (2009).
  • Santimaria M , MoscatelliG, VialeGLet al. Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res. 9(2), 571–579 (2003).
  • Perez L , AyalaM, PimentelGet al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen. Biotechnol. Appl. Biochem. 43, 39–48 (2006).
  • Wei LH , OlafsenT, RaduCet al. Engineered antibody fragments with infinite affinity as reporter genes for PET imaging. J. Nucl. Med. 49(11), 1828–1835 (2008).
  • Kobayashi H , SakaharaH, SagaTet al. A human mouse chimeric monoclonal antibody against Ca-125 for radioimmunoimaging of ovarian-cancer. Cancer Immunol. Immunother. 37(3), 143–149 (1993).
  • Ghetie V , PopovS, BorvakJet al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat. Biotechnol. 15(7), 637–640 (1997).
  • Kenanova V , OlafsenT, CrowDMet al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv–Fc antibody fragments. Cancer Res. 65(2), 622–631 (2005).
  • Yazaki PJ , KassaT, CheungCWet al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody–albumin fusion protein. Nucl. Med. Biol. 35(2), 151–158 (2008).
  • Kontermann RE . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs23(2), 93–109 (2009).
  • Kobayashi H , SakaharaH, HosonoMet al. Improved clearance of radiolabeled biotinylated monoclonal antibody following the infusion of avidin as a ‘chase‘ without decreased accumulation in the target tumor. J. Nucl. Med. 35(10), 1677–1684 (1994).
  • Milstein C , CuelloAC. Hybrid hybridomas and their use in immunohistochemistry. Nature305(5934), 537–540 (1983).
  • Goldenberg DM , RossiEA, SharkeyRM, McBrideWJ, Chang C-H. Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting. J. Nucl. Med.49(1), 158–163 (2008).
  • Ledoussal JM , GruazguyonA, MartinM, GautherotE, DelaageM, BarbetJ. Targeting of indium-111-labeled bivalent hapten to human-melanoma mediated by bispecific monoclonal-antibody conjugates – imaging of tumors hosted in nude-mice. Cancer Res.50(11), 3445–3452 (1990).
  • Sharkey RM , McBrideWJ, KaracayHet al. A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res. 63(2), 354–363 (2003).
  • McBride WJ , ZanzonicoP, SharkeyRMet al. Bispecific antibody pretargeting pet (immunoPET) with an I-124-labeled hapten-peptide. J. Nucl. Med. 47(10), 1678–1688 (2006).
  • Somasundaram C , MatzkuS, SchuhmacherJ, ZollerM. Development of a bispecific monoclonal-antibody against a Ga-67 chelate and the human melanoma-associated antigen p97 for potential use in pretargeted immunoscintigraphy. Cancer Immunol. Immunother.36(5), 337–345 (1993).
  • Ledoussal JM , ChetanneauA, GruazguyonAet al. Bispecific monoclonal antibody-mediated targeting of an indium-111-labeled DTPA dimer to primary colorectal tumors – pharmacokinetics, biodistribution, scintigraphy and immune-response. J. Nucl. Med. 34(10), 1662–1671 (1993).
  • Vuillez JP , MoroD, BrichonPYet al. Two-step immunoscintigraphy for non-small-cell lung cancer staging using a bispecific anti-CEA/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J. Nucl. Med. 38(4), 507–511 (1997).
  • Barbet J , PeltierP, BardetSet al. Radioimmunodetection of medullary thyroid carcinoma using indium-111 bivalent hapten and anti-CEA x anti-DTPA-indium bispecific antibody. J. Nucl. Med. 39(7), 1172–1178 (1998).
  • Hosono M , HosonoMN, Kraeber-BodereFet al. Two-step targeting and dosimetry for small cell lung cancer xenograft with anti-NCAM/antihistamine bispecific antibody and radioiodinated bivalent hapten. J. Nucl. Med. 40(7), 1216–1221 (1999).
  • Boerman OC , KranenborgM, OosterwijkEet al. Pretargeting of renal cell carcinoma: Improved tumor targeting with a bivalent chelate. Cancer Res. 59(17), 4400–4405 (1999).
  • Aarts F , BoermanOC, SharkeyRMet al. Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA x anti-di-diethylenetriaminepentaacetic acid F(ab´)2 antibody. Cancer 116(4), 1111–1117 (2010).
  • Kraeber-Bodere F , SalaunPY, OudouxA, GoldenbergDM, ChatalJF, BarbetJ. Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer. Cancer116(4), 1118–1125 (2010).
  • Karacay H , McBrideWJ, GriffithsGLet al. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti- In-DTPA bispecific antibody construct and a Tc-99m-Re-188-labeled peptide. Bioconjug. Chem. 11(6), 842–854 (2000).
  • Hnatowich DJ , VirziF, RusckowskiM. Investigations of avidin and biotin for imaging applications. J. Nucl. Med.28(8), 1294–1302 (1987).
  • Kalofonos HP , RusckowskiM, SiebeckerDAet al. Imaging of tumor in patients with indium-111-labeled biotin and streptavidin-conjugated antibodies – preliminary communication. J. Nucl. Med. 31(11), 1791–1796 (1990).
  • Lewis MR , WangM, AxworthyDBet al. In vivo evaluation of pretargeted Cu-64 for tumor imaging and therapy. J. Nucl. Med.44(8), 1284–1292 (2003).
  • Paganelli G , MagnaniP, ZitoFet al. 3-step monoclonal-antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51(21), 5960–5966 (1991).
  • Yao ZS , ZhangML, KobayashiHet al. Improved targeting of radiolabeled streptavidin in tumors pretargeted with biotinylated monoclonal-antibodies through an avidin chase. J. Nucl. Med. 36(5), 837–841 (1995).
  • Rusckowski M , QuT, ChangF, HnatowichDJ. Pretargeting using peptide nucleic acid. Cancer80(12), 2699–2705 (1997).
  • Liu GZ , Mang‘eraK, LiuN, GuptaS, RusckowskiM, HnatowichDJ. Tumor pretargeting in mice using Tc-99m-labeled morpholino, a DNA analog. J. Nucl. Med.43(3), 384–391 (2002).
  • Wang Y , ChangF, ZhangYet al. Pretargeting with amplification using polymeric peptide nucleic acid. Bioconjug. Chem. 12(5), 807–816 (2001).
  • He J , LiuGZ, GuptaS, ZhangYM, RusckowskiM, HnatowichDJ. Amplification targeting: a modified pretargeting approach with potential for signal amplification – proof of a concept. J. Nucl. Med.45(6), 1087–1095 (2004).
  • Verel I , VisserGWM, van Dongen GA. The promise of immuno-PET in radioimmunotherapy. J. Nucl. Med.46, 164S–171S (2005).
  • Wu AM . Antibodies and antimatter: the resurgence of immuno-PET. J. Nucl. Med.50(1), 2–5 (2009).
  • Aerts H , DuboisL, PerkLet al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 50(1), 123–131 (2009).
  • Achilefu S . Lighting up tumors with receptor-specific optical molecular probes. Technol. Cancer Res. Treat.3(4), 393–409 (2004).
  • Mahmood U , TungCH, TangY, WeisslederR. Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology224(2), 446–451 (2002).
  • Hilderbrand SA , WeisslederR. Near-infrared fluorescence: application to in vivo molecular imaging. Curr. Opin. Chem. Biol.14(1), 71–79 (2010).
  • Kosaka N , OgawaM, ChoykePL, KobayashiH. Clinical implications of near-infrared fluorescence imaging in cancer. Future Oncol.5(9), 1501–1511 (2009).
  • Ntziachristos V , BremerC, WeisslederR. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur. Radiol.13(1), 195–208 (2003).
  • Ntziachristos V , RipollJ, WeisslederR. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt. Lett.27(5), 333–335 (2002).
  • Ogawa M , KosakaN, ChoykePL, KobayashiH. H-type dimer formation of fluorophores: a mechanism for activatable, in vivo optical molecular imaging. ACS Chem. Biol.4(7), 535–546 (2009).
  • Tanaka K , MiuraT, UmezawaNet al. Rational design of fluorescein-based fluorescence probes, mechanism-based design of a maximum fluorescence probe for singlet oxygen. J. Am. Chem. Soc. 123(11), 2530–2536 (2001).
  • Miura T , UranoY, TanakaK, NaganoT, OhkuboK, FukuzumiS. Rational design principle for modulating fluorescence properties of fluorescein-based probes by photoinduced electron transfer. J. Am. Chem. Soc.125(28), 8666–8671 (2003).
  • Kamiya M , KobayashiH, HamaYet al. An enzymatically activated fluorescence probe for targeted tumor imaging. J. Am. Chem. Soc. 129(13), 3918–3929 (2007).
  • Urano Y , AsanumaD, HamaYet al. Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat. Med. 15(1), 104–109 (2009).
  • Kiyose K , KojimaH, NaganoT. Functional near-infrared fluorescent probes. Chem. Asian J.3(3), 506–515 (2008).
  • Jiang PJ , GuoZJ. Fluorescent detection of zinc in biological systems: recent development on the design of chemosensors and biosensors. Coord. Chem. Rev.248(1–2), 205–229 (2004).
  • Mahmood U , WeisslederR. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther.2(5), 489–496 (2003).
  • Tung CH , BredowS, MahmoodU, WeisslederR. Preparation of a cathepsin D sensitive near-infrared fluorescence probe for imaging. Bioconjug. Chem.10(5), 892–896 (1999).
  • Tung CH , MahmoodU, BredowS, WeisslederR. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res.60(17), 4953–4958 (2000).
  • Bremer C , BredowS, MahmoodU, WeisslederR, TungCH. Optical imaging of matrix metalloproteinase-2 activity in tumors: feasibility study in a mouse model. Radiology221(2), 523–529 (2001).
  • Bremer C , TungCH, BogdanovA, WeisslederR. Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology222(3), 814–818 (2002).
  • Tung CH , GersztenRE, JafferFA, WeisslederR. A novel near-infrared fluorescence sensor for detection of thrombin activation in blood. Chembiochem3(2–3), 207–211 (2002).
  • Shah K , TungCH, ChangCHet al. In vivo imaging of HIV protease activity in amplicon vector-transduced gliomas. Cancer Res.64(1), 273–278 (2004).
  • Galande AK , HilderbrandSA, WeisslederR, TungCH. Enzyme-targeted fluorescent imaging probes on a multiple antigenic peptide core. J. Med. Chem.49(15), 4715–4720 (2006).
  • Chen JQ , TungCH, MahmoodUet al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation105(23), 2766–2771 (2002).
  • Bremer C , NtziachristosV, WeitkampB, TheilmeierG, HeindelW, WeisslederR. Optical imaging of spontaneous breast tumors using protease sensing ‘smart‘ optical probes. Invest. Radiol.40(6), 321–327 (2005).
  • Jaffer FA , TungCH, GersztenRE, WeisslederR. In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler. Thromb. Vasc. Biol.22(11), 1929–1935 (2002).
  • Ogawa M , KosakaN, LongmireMR, UranoY, ChoykePL, KobayashiH. Fluorophore-quencher based activatable targeted optical probes for detecting in vivo cancer metastases. Mol. Pharm.6(2), 386–395 (2009).
  • Jares-Erijman EA , JovinTM. FRET imaging. Nat. Biotechnol.21(11), 1387–1395 (2003).
  • Kiyokawa E , HaraS, NakamuraT, MatsudaM. Fluorescence (Förster) resonance energy transfer imaging of oncogene activity in living cells. Cancer Sci.97(1), 8–15 (2006).
  • Elias DR , ThorekDLJ, ChenAK, CzuprynaJ, TsourkasA. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomark.4(6), 287–305 (2008).
  • Ogawa M , ReginoCAS, ChoykePL, KobayashiH. In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies. Mol. Cancer Ther.8(1), 232–239 (2009).
  • Ogawa M , KosakaN, ChoykePL, KobayashiH. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res.69(4), 1268–1272 (2009).
  • Kobayashi H , LongmireMR, OgawaM, ChoykePL, KawamotoS. Multiplexed imaging in cancer diagnosis: applications and future advances. Lancet Oncol.11(6), 589–595 (2010).
  • Kobayashi H , OgawaM, AlfordR, ChoykePL, UranoY. New strategies for fluorescent probe design in medical diagnostic imaging. Chem. Rev.110(5), 2620–2640 (2010).
  • Xu H , BaidooK, GunnAJet al. Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. J. Med. Chem. 50(19), 4759–4765 (2007).
  • Ogawa M , ReginoCAS, SeidelJet al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug. Chem. 20(11), 2177–2184 (2009).
  • Yang J , LimEK, LeeHJet al. Fluorescent magnetic nanohybrids as multimodal imaging agents for human epithelial cancer detection. Biomaterials 29(16), 2548–2555 (2008).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.